NCT02557321View on ClinicalTrials.gov

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

May 31, 2023

Study Completion Date

April 30, 2025

Conditions
Melanoma
Interventions
DRUG

PV-10

PV-10 will be administered by intralesional injection every 3 weeks at Day 1 (Week 1), Week 4, Week 7, Week 10 and Week 13

DRUG

Pembrolizumab

Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)

Trial Locations (5)

18045

St Luke's University Health Network, Easton

33612

Moffitt Cancer Center, Tampa

77230

MD Anderson Cancer Center, Houston

97239

Oregon Health & Science University, Portland

03756

Dartmouth-Hitchcock Medical Center, Lebanon

All Listed Sponsors
lead

Provectus Biopharmaceuticals, Inc.

INDUSTRY

NCT02557321 - PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma | Biotech Hunter | Biotech Hunter